The quest for sustained multiple morbidity reduction in very low-birth-weight infants: the Antifragility project. by Kaempf, Joseph et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
6-1-2017 
The quest for sustained multiple morbidity reduction in very low-
birth-weight infants: the Antifragility project. 
Joseph Kaempf 
Providence St. Joseph Health 
N M Schmidt 
Women and Children's Program, Department of Neonatology, Providence St. Vincent Medical Center, 
Portland, OR, USA. 
S Rogers 
Women and Children's Program, Department of Neonatology, Providence St. Vincent Medical Center, 
Portland, OR, USA. 
C Novack 
Women and Children's Program, Department of Neonatology, Providence St. Vincent Medical Center, 
Portland, OR, USA. 
M Friant 
Women and Children's Program, Department of Neonatology, Providence St. Vincent Medical Center, 
Portland, OR, USA. 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Obstetrics and Gynecology Commons, and the Pediatrics Commons 
Recommended Citation 
Kaempf, Joseph; Schmidt, N M; Rogers, S; Novack, C; Friant, M; Wang, L; and Tipping, N, "The quest for 
sustained multiple morbidity reduction in very low-birth-weight infants: the Antifragility project." (2017). 
Articles, Abstracts, and Reports. 2275. 
https://digitalcommons.psjhealth.org/publications/2275 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Joseph Kaempf, N M Schmidt, S Rogers, C Novack, M Friant, L Wang, and N Tipping 




The quest for sustained multiple morbidity reduction in very
low-birth-weight infants: the Antifragility project
JW Kaempf, NM Schmidt, S Rogers, C Novack, M Friant, L Wang and N Tipping
OBJECTIVE: Can a comprehensive, explicitly directive evidence-based guideline for all therapies that might affect the major
morbidities of very low-birth-weight (VLBW) infants help a neonatal intensive care unit (NICU) further improve generally favorable
morbidity rates? Can Antifragility principles of provider adaptive growth from stressors, enhanced infant risk assessment and
adherence to effective therapies minimize unproven treatments and reduce all morbidities?
STUDY DESIGN: Prospectively planned observational trial in VLBW infants: control group born October 2011 to September 2013
and study group October 2013 to September 2015. Multi-disciplinary evidence-based review assigned all NICU treatments into one
of four distinct categories: (1) always employ this therapy for VLBW infants, (2) never use this therapy, (3) employ this questionable
therapy thoughtfully, only in certain circumstances and (4) this therapy has insufficient evidence of efficacy and safety. Extensive
staff education emphasized evidence-based potentially better practice (PBP) selection with compliance checks, appreciation of
intertwined co-morbidities and prioritizing infant risk reduction strategies.
RESULTS: Control included 221 infants, mean (s.d.) age 29 (2.6) weeks, birth weight 1129 (257) g and Study included 197 infants, 29
(2.7) weeks, 1093 (292) g. One hundred and four distinct therapies were placed into categories 1 to 4, with 32 specific compliance
checks. Overall mean compliance with the process checks during the second era was 70%, high: 100% (exclusive breast milk use),
low: 24% (correct pulse oximetry alarm settings). Morbidity and mortality rates did not significantly change during the second era.
CONCLUSIONS: In our NICU with favorable morbidity rates, an expanded effort using a comprehensive therapy guideline for VLBW
infants did not further improve outcomes. We need deeper understanding of continuous quality improvement (CQI) fundamentals,
therapy compliance, co-morbidity relationships and enhanced sensitivity of risk assessment. Our innovative Antifragility PBP
guideline could be useful to other NICUs seeking improvement in VLBW infant morbidities, as we offer a reasoned and concise
template of a broad array of therapies categorized efficiently for transparency and review, designed to enhance responsible CQI
decision-making.
Journal of Perinatology (2017) 37, 740–746; doi:10.1038/jp.2017.7; published online 16 February 2017
INTRODUCTION
Open sharing of continuous quality improvement (CQI) experience
is crucial, even when projects are not successful, because learning
accelerates at the intersection of careful documentation and
transparency. The reduction of certain neonatal intensive care unit
(NICU) morbidities driven by evidence-based principles of CQI is
encouraging.1,2 The Vermont Oxford Network (VON) has cham-
pioned multidisciplinary collaboration and potentially better
practice (PBP) sharing within its membership achieving significant
reductions over the past 25 years in any late infection and
retinopathy of prematurity in very low-birth-weight (VLBW)
infants.1 VON CQI tools are particularly enticing for NICUs with
comparatively high morbidity rates, because adopting funda-
mental CQI techniques reliably reduces unfavorable rates to at
least average percentiles. Our next challenge is to develop
dependable CQI blueprints that guide sustained multiple morbid-
ity reduction to top quartile percentiles, thus far an elusive goal.3,4
What about NICUs experienced with traditional evidence-based
medicine (EBM) and CQI techniques that already have favorably
low morbidity rates? How can these NICUs sustain progress and
how can the intricate relationships among potentially competing
co-morbidities be better understood? For example, which NICUs
reliably minimize chronic lung disease and retinopathy of
prematurity, while also consistently reducing the burden of any
late infection, necrotizing enterocolitis and intraventricular
hemorrhage, and how exactly is this done? Despite impressive
progress in NICU CQI, there is currently no published detailed CQI
instructional guideline that reliably leads to sustained, multiple
morbidity reduction.
Antifragility is the ability of adaptive individuals or organizations
to absorb, integrate and not just withstand stressors but actually
improve from challenge—hormesis. As described by Taleb5, a
wide swath of human endeavors throughout history strongly
suggests that successful people and groups share a common
feature—the adroit ability to weigh the upside and downside of
critical decisions, with an embedded appreciation of the highly
nonlinear relationship of many cause-and-effect connections. The
conception of ‘Black Swan’ events by Taleb5 (unpredicted, rare
cataclysms that immediately alter accepted paradigms) and the
pivotal moral nature of Antifragility, that is, if I have skin-in-the-
game, and cannot transfer that risk to you, then we make adaptive
decisions together thoughtfully, are valuable insights we think are
relevant to EBM and NICU CQI.
The purpose of this study is to share how our NICU, an
experienced 20-year participant in formal local and national CQI
activities, but puzzled and frustrated by a lack of sustained
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improvement, has attempted to excel by understanding Anti-
fragility and infusing its principles into our daily EBM decision-
making. We provide for scrutiny the following: (a) an unusually
detailed template of PBP classification for all the major VLBW
infant morbidities, (b) specific bedside compliance measure-
ments for each morbidity typically scarce in CQI reports, (c) a
comprehensive morbidity rate report and (d) speculation regard-
ing the challenges and possible limitations inherent to current CQI
methodology.
METHODS
The Providence Health System institutional review board approved this
investigation. Providence St. Vincent Medical Center (PSVMC) has a Level 3
NICU and this was a prospectively planned observational trial using a
historical control group. Our population included all inborn VLBW infants
401 to 1500 g, delivered 1 October 2011 to 30 September 2013 (Era 1
Control Group), compared with those delivered 1 October 2013 to 30
September 2015 (Era 2 Antifragility Group). The PSVMC NICU has been a
member of the VON since 1995 and has participated in many organized
CQI activities related to the VON NICQ collaborative.6
In January 2013, we began an ambitious project: (a) review our history of
CQI activities and the year-to-year VLBW infant mortality and morbidity
rates so that everyone understood our early success (‘low-hanging fruit’)
followed by variable morbidity improvement stagnation (‘high or hidden
fruit’); (b) introduce the principles of Antifragility, hormesis, risk assessment
and complex cause-and-effect relationships; (c) carefully review every
possible therapy that might be used in our NICU to prevent or treat one or
more of the nine major morbidities of prematurity and conduct
comprehensive literature reviews. We then (d) assigned by consensus
every therapy to one of four ‘Antifragility Categories’—(1) do this virtually
every time for every VLBW infant; (2) never do this; (3) apply this therapy in
certain circumstances, but thoughtfully with careful upside/downside
considerations; and (4) this therapy is of uncertain efficacy and safety so
optimal use is unknown—(e) selected two or more compliance checks for
each of the nine morbidities; and (f) committed to an every 3-month
review for 2 years of VLBW infant outcomes, adherence with the
compliance checks and feedback to all NICU staff. A PBP was defined as
an Antifragility category 1 or category 3.
Evidence-based review of NICU therapies was facilitated by subdividing
into the nine major VLBW infant morbidities (chronic lung disease, any
late infection, grade 3 to 4 intraventricular hemorrhage, periventricular
leukomalacia, stage 3 to 4 retinopathy of prematurity, necrotizing
enterocolitis, focal intestinal perforation, patent ductus arteriosus and
discharge weight o10th percentile) using the VON definitions.7 Each of
the nine morbidities was assigned to one PSVMC neonatologist who led a
comprehensive review of the published literature and categorized all
potential therapies into the antifragility categories described in ‘c’ and ‘d’.
Our anchor—‘Has this therapy been rigorously shown to safely and
effectively prevent or treat Morbidity X?’ If not, is it unsafe and ineffective,
or was there an exceptional, reasoned indication for the practice, or do we
simply not know? This Antifragility consensus PBP guideline was also
circulated to six national experts in NICU CQI for review and comments.
For 2 months before our ‘go-live’ date of 1 October 2013, we thoroughly
discussed the Antifragility project with our NICU staff using multiple
forums (bedside rounds, conferences, email alerts and posters). Multi-
pronged CQI projects often have inexact implementation dates and we
were aware that our NICU historically did not have comprehensive
compliance data for many of our common therapies. To address this issue
we underscored that detailed, formal PBP compliance data would begin
1 October 2013, and that this exact start date would motivate staff to
follow the Antifragility PBP guidelines. We emphasized the complex nature
of intertwined co-morbidities, the limited number of truly safe, effective
therapies, the need for constant process and outcomes review, the largely
unmeasured cultural and human factors that affect CQI, the acceptance of
personal and group responsibility for the risk and uncertainty of NICU care
and transparent decision-making.
For between era comparisons, χ2- or Fisher’s exact test were used for
categorical variables and t-test or Wilcoxon’s rank-sum test were used for
continuous variables. The 2014 entire VON outcomes were used as
benchmarks to evaluate the results of the Era 2 Antifragility Group, so the
exact binomial test was used for categorical variables and t-test for the
length of stay. Statistical analysis was performed using R 3.1.0 statistical
program (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Table 1 shows no significant differences in the demographic
descriptors comparing the two eras (except fewer Era 2 multiple
births). Our NICU’s VON risk adjusters in Table 1, as well as
gestational age and birth weight distribution are similar to the entire
VON (data available at Nightingale Electronic Reporting System).
Table 2 summarizes the ‘Antifragility Potentially Better Practice
Schema’. The nine major morbidities and all 104 therapies PSVMC
considered as possible treatments were placed into one of four
distinct categories. Table 3 lists our 32 consensus choices for detailed
compliance checks, at least two for each morbidity, acknowledging
that limitations of time, resources and understanding of cause-and-
effect necessarily led to practical measurements.
Overall compliance with the process checks (averaged within
each of the 32 categories, then each category weighted equally)
was 70%, from a high of 100% (exclusive breast milk use, no milk
thickeners, head of bed elevated, no concurrent use of
prostaglandin synthase inhibitors and corticosteroids, and daily
use of total parenteral nutrition calculator), to a low of 24%
(correct pulse oximeter alarm settings). Table 4 lists the PSVMC
mortality and morbidity rates in our two study eras and, for
comparison, the 2014 entire VON. Eight of the nine major
morbidity rates trended lower in our Era 2 Antifragility Group
compared with the VON, three of them significantly. Mortality also
trended lower at PSVMC and our total length of stay in survivors
was significantly shorter than the VON. There were no significant
changes in any outcome comparing the PSVMC Era 1 Control
Group with the Era 2 Antifragility Group.
DISCUSSION
Proven EBM methodology that reduces all major VLBW infant
morbidities to sustained low rates has proven elusive for the vast
majority of NICUs.1–4 We have provided a transparent, concise yet
broad, EBM guideline that contains most potential therapies
thought to reduce the burden of the nine major VLBW infant
morbidities. A succinct four category PBP classification schema
(Table 2 and updated in Supplementary Table S1) and detailed
compliance checks (Table 3 and updated in Supplementary
Table S2) has, to our knowledge, never been published. Even
when CQI projects are disappointing, publishing well-documented
experience disseminates valuable experience, an essential goal
encouraged by EBM experts.8–11
We believe the principles of Antifragility—an interpretation of
human cognition and behavior broadly evident in modern
Table 1. Demographic descriptors of the Era 1 Control Group and the











29.2 (2.6) 29.0 (2.7) 0.44
Birth weight, g
mean (s.d.)
1129 (257) 1093 (292) 0.18
Male gender 109/221 (49%) 96/197 (49%) 0.98
Multiple birth 91/221 (41%) 57/197 (29%) 0.01
Major birth defect 2/221 (1%) 4/197 (2%) 0.43
Antenatal steroids 208/221 (94%) 190/197 (96%) 0.38
Vaginal birth 54/221 (24%) 45/197 (23%) 0.79
1 Min APGAR o4 41/221 (19%) 45/197 (23%) 0.34
Chorioamnionitis 61/221 (28%) 59/197 (30%) 0.67
Maternal
hypertension
78/221 (35%) 71/197 (36%) 0.95
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Table 2. The Antifragility Potentially Better Practices Schema to improve outcomes in VLBW infants
Morbidity Category 1 practices Category 2 practices Category 3 practices Category 4 practices
Virtually always Virtually never Apply thoughtfully, sometimes Unknown efficacy and safety
Chronic lung disease Antenatal corticosteroids
NCPAP before mechanical ventilationa
Minimize ventilator usea




Saturation alarms 84% and 96%a
Avoid PCO2 o40 or 469
Early corticosteroids (o7 days old)
Routine surfactant for mild RDS
Routine high frequency ventilation
Routine diuretics
Gentle ventilation (tidal volume 4–5 cc kg− 1,
permissive hypercarbia)a
PDA guidelinesa
High flow nasal cannulaa
NIPPVa
High frequency ventilation





NCPAP weaning protocols to room
air, high flow nasal cannula or low
flow nasal cannula






Omega 3 fatty acids
Any late infection Hand hygiene every encounter
Breast milk
Central line care bundlea
48 h hard-stop for antibiotics in rule out
sepsis work-upsa
Pharmacy sterile prep procedures
Minimize postnatal corticosteroids
Appropriate pre-incision antibiotics
Prolonged or broad spectrum
antibiotic courses without a
specific indication
Routine antacids
Intravenous immune globulin for
suspected or proven sepsis





Debriefing nosocomial infection cases










Delayed umbilical cord clampinga
Routine sedation, airway
suctioning, fluid boluses, NaHCO3
and/or pro-coagulants
Small baby guidelinesa: head and body
positioning, with pain, light, sound stimuli
reduction
Cardiovascular instability: treatment of
significant hypotension and poor perfusion
with pressors and volume expanders




Optimal airway suctioning practice
High frequency ventilation




Avoid hypocarbia PCO2 o35 with assisted
ventilation
Cardiovascular instability: treatment of
significant hypotension, poor perfusion
Minimize hypoxic episodes
Anti-inflammatory agents




Saturation targetsa If o30 weeks at birth
88-95% until 32 weeks CGA then 94-98%
at 4/= 32 weeks corrected gestational age
Breast milk
100% FiO2 resuscitation





Hyperglycemia and insulin use reduction
Bevacizumab
Omega 3 fatty acids













Human milk-based fortifier (Prolacta)a
Milk thickeners
Prolonged or broad spectrum
antibiotic courses without a
specific indication
Routine antacids
Routine cow’s milk formula
Optimal feeding guideline
RBC transfusions and feeding
Withholding all cow’s milk products
Gastric residual checks
Optimal PSI use
Lactoferrin, growth factors, EPO, O3
FA
























Table 2. (Continued )
Morbidity Category 1 practices Category 2 practices Category 3 practices Category 4 practices
Virtually always Virtually never Apply thoughtfully, sometimes Unknown efficacy and safety
Focal intestinal
perforation
Early and/or concurrent use of
indomethacin and corticosteroids
Trophic breast milk feeds Optimal PSI use
Enteral sterile water
Umbilical line placement and
duration
Patent ductus arteriosus Antenatal corticosteroids Indomethacin or any PSI for an
asymptomatic or early PDA
Not treating a large, symptomatic
PDAa
PDA Guidelinesa
Indomethacin or acetaminophen or
ibuprofen or a combination of drugs
Oral vs. Intravenous PSI









Day 1 TPN/IL with early calorie, protein,
and fat goals met within 1 weeka
Early breast milk feedsa
Fortifiers to BRM to enhance calorie,
protein and fat requirementsa
Improper feeding pump and
tubing usea




Optimal growth rate and growth
chart
Optimal fortifier
Optimal protein and calorie intake
Prokinetics
Q2h v. Q3h v. continuous feeds
Nippling skills teaching and aids
Abbreviations: BRM, breast milk; CV, cardiovascular; EPO, erythropoietin; HFNC, high flow nasal cannula; NICU, neonatal intensive care unit; NCPAP, nasal continuous positive airway pressure; NIPPV, non-invasive
positive pressure ventilation; O3 FA, omega 3 fatty acids; PDA, patent ductus arteriosus; PSI, prostaglandin synthase inhibitor; RBC, red blood cell; RDS, respiratory distress syndrome; TPN/IL, total parenteral
nutrition and intralipid; VAP, ventilator-associated pneumonia; VLBW, very low birth weight.
Category 1 practice: Always, this should be done virtually every time for every VLBW infant in the appropriate scenario. Strong published evidence exists to support its effectiveness and safety. Category 2
practice: Never, this should virtually never be done, strong evidence suggests it is ineffective, unsafe and/or wasteful. Category 3 practice: Sometimes, this may be effective in certain VLBW infants in particular
clinical situations. More studies and evidence are needed before we adopt, refine or reject this as a therapy. As there is questionable and variable overall effectiveness and safety, these practices should be
thoughtfully applied with careful measurement and review of its application. Category 4 practice: Unknown, there is insufficient evidence to determine whether this is helpful or ineffective, safe or harmful.
Optimal use is unknown; we should generally minimize use and, when employed, measure and review its application.






















Table 3. PBP process measures and compliance checks during the Era 2 Antifragility Group
Morbidity PBP process check Compliance Comments
Chronic lung disease Antenatal corticosteroids 96%
Bubble nasal NCPAP before intubation and
mechanical ventilation
54% Full NCPAP set-up before ventilator
was employed
Any mechanical ventilation 36% During entire NICU stay
Caffeine within 24 h of birth 95% If needing any respiratory support





88–95% was the target
94–98% after 32 weeks CGA if born at
o30 weeks 1584 audits
Oxygen saturation pulse oximeter alarms set
correctly
1584 random audits




Alarm set 1% above the upper target
Low alarm setting 24% Correct
47% Too high
28% Too low
Alarm set 4% below the lower target
PCO2 o40 mm Hg
PCO2 o30 mm Hg




Blood gas values first 48 h of life if
mechanically ventilated
Any late infection Hand washing audits 97% ‘Secret spy’ 1202 random audits
Hard stop antibiotics at 48 h of age for ‘Rule Out
Sepsis’ work-up initiated at birth
72% Blood culture negative infants
Hard stop antibiotics at 48 hours for – ‘Rule Out
Sepsis’ work-up initiated after Day 3 of life
34% Blood culture negative infants
Avoid postnatal corticosteroid use 95% 5% of infants were exposed
Breast milk only until 33 weeks corrected
gestational age
100%






Head of bed elevated first 72 h of life 100%
Head midline first 72 h of life 86%
No sodium bicarbonate first week of life 99%
Periventricular leukomalacia PCO2 o40 mm Hg
PCO2 o30 mm Hg
16%
3%
Blood gas values first 48 h of life if
mechanically ventilated
Stage 3–4 retinopathy of
prematurity
See oxygen saturation pulse oximetry alarms and
targets with Chronic lung disease
See Chronic lung
disease
Breast milk only until 33 weeks corrected
gestational age
100%
Necrotizing enterocolitis Antenatal corticosteroids 96%
Breast milk only until 33 weeks corrected
gestational age
100%
Human milk fortifier (Prolacta) not cow’s milk
based
82%
Feeding guideline adherence first 3 weeks of life 85%
No milk thickeners 100%
Focal intestinal perforation No concurrent use of indomethacin or ibuprofen
and corticosteroids
100%
Patent ductus arteriosus Antenatal corticosteroids 96%
No PDA pharmacologic therapy during the first
week of life
65% 35% Received prostaglandin synthase
inhibitors first week
Avoid surgical ligation 95% 5% ligation rate
Discharge weight less than 10th
percentile
Total parenteral nutrition started Day 1 96%
Intralipid started Day 1 82%
Intravenous kcal goal met Day 4 Median
Intravenous protein goal met Day 3 Median
Enteral kcal goal met Day 13 Median
Enteral protein goal met Day 16 Median
Feeding guideline adherence first 3 weeks of life 85%
Own mother’s breast milk at discharge 77%
Computerized TPN calculator used daily 100%
Abbreviations: CGA, corrected gestational age; NCPAP, nasal continuous positive airway pressure; PBP, potentially better practice; PDA, patent ductus
arteriosus; TPN, total parenteral nutrition.
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history—adds insight to how neonatologists and NICU staff make
decisions, for better or worse.5 Antifragility emphasizes hormesis
(adapting and improving from stressors) and appreciating the
difference between uncertainty and risk. Uncertainty means you
do not know what will happen, risk is the product of harm and the
chance it will happen. Unlike families, NICU providers may conflate
uncertainty and risk, too easily transferring risk (our vulnerability
and responsibility) to the group and inevitably to the infant.12
Table 3 (compliance data that is scarce in many CQI reports)
suggests the poorest adherence with PBPs largely resided among
those activities in which risk could be transferred from the
individual provider to the group and/or the baby.
Table 3 lists examples of possible risk transfer that undermine
NICU CQI as follows: (a) it may be easier for a neonatologist to
intubate a premature infant rather than try nasal continuous
positive airway pressure with all the attendant patience, skill and
serial exams required, (b) nurses widen saturation targets to lessen
annoying and disruptive pulse oximeter alarms, or to ‘keep the
baby pink’, (c) to stabilize newborns’ immediate respiratory needs
neonatologists may mechanically over-ventilate, (d) antibiotics are
started and maintained beyond 48 h despite negative cultures,
and (e) the patent ductus arteriosus is treated early without
objective evidence of shunt harm.
We did not demonstrate significant reduction in the major
VLBW infant morbidities; thus, why should our proposed CQI
model be reasonable to consider? First, we acknowledge the
limitations of our CQI efforts as follows: (a) most NICU
therapies are not supported by the strong Level 1 evidence of
randomized, controlled trials (Table 2) so we would not nece-
ssarily expect sustained morbidity reduction to low rates, (b)
there was variable compliance with our PBPs, just 70% overall,
range 24 to 100% (Table 3), (c) time and resource constraints,
and (d) uneven understanding of EBM and CQI principles.11 In
addition, our NICU morbidity rates in the Era 1 Control Group
were generally favorable (Table 4), for example, any late
infection (4%) and grade 3 to 4 intraventricular hemorrhage
(2%); thus, further improvement is not easily guided by
customary means.
It may be unrealistic to think we can reduce certain morbidities
similar to stage 3 to 4 retinopathy of prematurity, any late
infection or periventricular leukomalacia from recent low rates to
near zero. So much pathophysiology is unclear with these
morbidities that it is unlikely traditional CQI methodology alone
will be successful. Nevertheless, there are multiple sensible
strategies to reduce some major morbidities, PBPs of little risk to
the NICU provider, for example, hand washing, breast milk, fewer
ventilator days and limiting unnecessary medications.1–4
Although we categorized 104 distinct NICU VLBW infant
therapies into the four Antifragility PBP categories, creating a
user-friendly EBM guideline (Table 2), there are possibly other
effective therapies not listed and any PBP prioritization needs to
be updated as more evidence accumulates (see Supplementary
Table 1). We selected 32 distinct compliance checks by con-
sensus and practicality; not only was compliance considerably
o100% with some PBPs (Table 3), but others were not formally
monitored, for example, effects of placental transfusion.13 Many
PBPs are proposed for VLBW infants, but the variable appli-
cation and effects are often not rigorously quantified, making it
exceedingly difficult for NICUs to confidently know why they
are improving (or not). An observational trial similar to ours is
limited by possible unmeasured practice changes and
unforeseen differences in the VLBW infants between the two
eras.14,15
Our CQI experience also suggests a ‘tragedy of the commons’
embedded within group dynamics—individual providers acting
independently can repeatedly make decisions that reduce their
own risk or inconvenience at the expense of group goals and the
infant’s best interests. Many modern day problems not only resist
purely technical approaches, but are exacerbated by short-term
quasi-solutions to complexities that inevitably create even more
perplexing residual difficulties, which are exceedingly recalcitrant
and costly to solve.16–20 Recognizing this, authorities such as
Davidoff21 believe CQI is fundamentally a moral activity; improve-
ment science should be on par with beneficence, non-malefi-
cence, autonomy and justice. This is congruent with Antifragility
principles: how do we foster a moral CQI symbiosis of (a) knowing
what to do, (b) how to do it reliably, (c) family preference and (d)
societal priorities.22–25
We continue our study in a third 2-year era (2016–17) with
both an updated PBP guideline and an expanded compliance
checklist (Supplementary Tables S1 and S2). Perceptively
evaluating the favorable versus unfavorable asymmetry inh-
erent in virtually every NICU decision embodies Antifragility;
every medical intervention is an amalgam of uncertainty, risk,
preference and cost—variables exceedingly challenging to
measure.





P-valuea Vermont Oxford Network
mean (interquartile) 2014
P-valueb
Chronic lung disease 46/221 (21%) 50/197 (25%) 0.32 24% (11, 30) 0.68
Any late infection 8/215 (4%) 8/195 (4%) 40.999 12% (4, 15) o0.001
Grade 3–4 intraventricular hemorrhage 5/211 (2%) 9/190 (5%) 0.31 7% (2, 9) 0.26
Periventricular leukomalacia 5/211 (2%) 2/190 (1%) 0.45 3% (0, 4) 0.14
Stage 3–4 retinopathy of prematurity 8/191 (4%) 8/155 (5%) 0.86 6% (0, 8) 0.87
Necrotizing enterocolitis (NEC) 9/221 (4%) 3/197 (1.5%) 0.15 5% (0, 6) 0.02
Focal intestinal perforation 3/221 (1%) 2/197 (1%) 40.999 2% (0, 2) 0.45
Patent ductus arteriosus 43/221 (20%) 49/197 (25%) 0.22 28% (14, 37) 0.78
Avoid pharmacologic therapy during week 1 32/49 (65%)
Ligation 8/221 (4%) 10/197 (5%) 0.62 4% (0, 5) 0.95
Discharge weight o10th percentile 74/196 (38%) 79/179 (44%) 0.25 53% (42, 66) 0.02
Mortality excluding early death 18/216 (8%) 12/195 (6%) 0.51 9% (5, 13) 0.21
Length of stay, mean (s.d.) (total hospital stay in
days in survivors)
59 (26) 56 (26) 0.31 68 (58, 73) o0.001
Vermont Oxford Network data accessed at the Nightingale Electronic Reporting System. aComparing Providence St. Vincent Medical Center Era 1 Control
Group and Era 2 Antifragility Group. bComparing Providence St. Vincent Medical Center Era 2 Antifragility Group with the Vermont Oxford Network averages
for 401–1500 g inborn infants in 2014.
Quest for sustained multiple morbidity reduction
JW Kaempf et al
745
Journal of Perinatology (2017), 740 – 746
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This investigation was supported by the Providence Health and Services Foundation
(Portland, OR) and Northwest Newborn Specialists, PC (Portland, OR). The sponsors
had no role in the design or conduct of the study. We thank the entire PSVMC
Antifragility Team including Jody Bellant, Sara Clark, Kati Knudsen, Jennifer Niemeyer,
Yvette Rice-Rosenthal, Kandace Ryan and Melissa Stawarz for their many contribu-
tions to this team effort.
AUTHOR CONTRIBUTIONS
The principal investigator JWK, MD, had full access to the data in the study and
takes responsibility for the integrity and accuracy of the data analysis. The
source of the data was our PSVMC comprehensive NICU database (NICPOP) and
collection tools, as well as the Vermont Oxford Database accessible at the
Nightingale Electronic Internet Reporting System. JWK was responsible for the
original conception and design of the study and drafted the first and final
versions of the manuscript. Co-authors NMS, SR, CN, MF, LW and NT assisted in
implementation of the project, critical review of the manuscript at each step, all
data analysis and participated in the manuscript formulation and final revision.
REFERENCES
1 Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA et al. Mortality
and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009.
Pediatrics 2012; 129: 1019–1026.
2 Ellsbury DL, Clark RH, Ursprung R, Handler DL, Dodd ED, Spitzer AR. A multifaceted
approach to improving outcomes in the NICU: the Pediatrix 100,000 babies
campaign. Pediatrics 2016; 137(4): e20150389.
3 Kaempf JW, Zupancic JAF, Wang L, Grunkemeier GL. A risk-adjusted, composite
outcomes score and resource utilization metrics for very low-birth-weight infants.
JAMA Pediatrics 2015; 169(5): 459–465.
4 Dukhovny D, Pursley DM, Kirpalani HM, Horbar JH, Zupancic JAF. Evidence,
quality, and waste: solving the value equation in neonatology. Pediatrics 2016;
137(3): e20150312.
5 Taleb N. Antifragile: Things That Gain from Disorder. Random House: New York,
2012.
6 Horbar JD, Soll RF, Edwards WH. The Vermont Oxford Network: a community of
practice. Clin Perinatol 2010; 37(1): 29–47.
7 Vermont Oxford Network Database Manual of Operations. Release 19.0. Vermont
Oxford Network: Burlington, 2014.
8 Berwick DM. The science of improvement. JAMA 2008; 299(10): 1182–1184.
9 Van Cleave J, Dougherty D, Perrin JM. Strategies for addressing barriers to pub-
lishing pediatric quality improvement research. Pediatrics 2011; 128(3): e678–e686.
10 Chassin MR, Loeb JM, Schmaltz SP, Wachter RM. Accountability measures – using
measurement to promote quality improvement. N Engl J Med 2010; 363(7): 683–688.
11 Casarett D. The science of choosing wisely – overcoming the therapeutic illusion.
N Engl J Med 2016; 374(13): 1203–1205.
12 Ralston SL, Schroeder AR. Doing more vs doing good: aligning our ethical principles
from the personal to the societal. JAMA Pediatrics 2015; 169(12): 1085–1086.
13 Kaempf JW, Tomlinson MW, Kaempf AJ, YingXing Wu, Wang L, Tipping N et al.
Delayed umbilical cord clamping in premature infants. Ob Gyn 2012; 120(2):
325–330.
14 Profit J, Gould JB, Bennett M, Goldstein BA, Draper D, Phibbs CS et al. The asso-
ciation of level of care with NICU quality. Pediatrics 2016; 137(3): e20144210.
15 Blumenthal D. Better health care: a way forward. JAMA 2016; 315(3): 1333–1334.
16 Hardin G. The tragedy of the commons. Science 1968; 162(3859): 1243–1248.
17 Schwartz E. Overskill: The Decline of Technology in Modern Civilization. Quadrangle
Books: Chicago, 1971.
18 Callahan D. False Hopes: Overcoming the Obstacles to a Sustainable, Affordable
Medicine. Rutgers University Press: New Brunswick, New Jersey, 1999.
19 Silverman WA. Human Experimentation: A Guided Step into the Unknown. Oxford
University Press: Oxford, England, 1985.
20 Gray J. Straw Dogs. Granta Publications: London, England, 2002.
21 Davidoff F. Systems of service: reflections on the moral foundations of
improvement. BMJ Qual Saf 2011; 20: i5–i10.
22 Kaempf JW, Tomlinson MW, Tuohey J. Extremely premature birth and the choice
of neonatal intensive care versus palliative comfort care: an 18-year single-center
experience. J Perinatol 2016; 36: 190–195.
23 Kelly MP, Heath I, Howick J, Greenhalgh T. The importance of values in evidence-
based medicine. BMC Med Ethics 2015; 16(69): 1–8.
24 Wilkinson D, Chalmers I, Cruz M, Tarnow-Mordi W. Dealing with the unknown:
reducing the proportion of unvalidated treatments offered to children. Arch Dis
Child Fetal Neonatal Ed 2015; 100(3): F190–F192.
25 Lefkowitz W, Jefferson TC. Medicine at the limits of evidence: the fundamental
limitation of the randomized clinical trial and the end of equipoise. J Perinatol
2014; 34: 249–251.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Journal of Perinatology website (http://www.nature.com/jp)
Quest for sustained multiple morbidity reduction
JW Kaempf et al
746
Journal of Perinatology (2017), 740 – 746
